Remifentanil was designed to serve as a strong anesthetic with an ultra-short and predictable duration that would not have accumulation issues. Remifentanil is patented by Glaxo Wellcome Inc. and was FDA approved on July 12, 1996. Pricing for Ultiva. 1 mg vial - 30.19 USD; 3 mg vial - 57.20 USD; 5 mg vial - 118.15 USD
Breach of contract is a legal cause of action in which a binding agreement or bargained-for exchange is not honored by one or more of the parties to the contract by non-performance or interference with the other party's performance.
In contract law, a material breach of contract is a breach (a failure to perform the contract) that strikes so deeply at the heart of the contract that it renders the agreement irreparably broken and defeats the purpose of making the contract in the first place.